Selank Interactions: Alcohol, Caffeine, Food and Compounds in the Literature

What "interaction" means in the Selank literature

Selank is a synthetic heptapeptide analogue of the immunopeptide tuftsin that has been studied mainly in Russian preclinical and clinical settings as an anxiolytic and cognition-related compound. When readers ask about "interactions," they usually mean one of three different things: a pharmacokinetic interaction (one substance changing how much of another reaches the brain), a pharmacodynamic interaction (two substances acting on overlapping systems), or a safety interaction (an adverse event that appears only when substances are combined). The published Selank record addresses the second category in a handful of animal and cell models, touches the third only indirectly, and contains essentially nothing on the first.

This page reports what the identified studies examined and what they reported. Where no study exists for a commonly asked pairing, that is stated as an absence of evidence, and any reasoning offered is explicitly labelled as mechanistic speculation rather than a finding. This page is for educational purposes only and is not medical advice; consult a licensed physician about anything relating to your own health, medications or research protocols.

Selank and alcohol: the most studied pairing

Ethanol is the only substance with more than one dedicated Selank co-exposure study in the identified literature, and all of that work was performed in rodents.

Ethanol-induced hyperlocomotion and behavioural sensitisation

A 2016 study in DBA/2 mice reported that Selank inhibited ethanol-induced hyperlocomotion and the manifestation of behavioural sensitisation, a model used to probe the neuroadaptations that follow repeated alcohol exposure (PMID 27878720). Behavioural sensitisation in this paradigm refers to a progressively larger locomotor response to the same ethanol challenge across repeated administrations, and the researchers used it as a behavioural readout rather than as a measure of intoxication in humans (PMID 27878720).

Ethanol and memory in rats

A 2019 rat study reported that Selank, described by the authors as a peptide analogue of tuftsin, protected against ethanol-induced memory impairment and that this was accompanied by regulation of brain-derived neurotrophic factor (BDNF) content in the hippocampus and prefrontal cortex (PMID 31625062). The study measured a neurotrophin marker in two brain regions alongside a behavioural memory outcome, which is a pharmacodynamic observation in an animal model and not a demonstration that Selank changes alcohol's effects in people (PMID 31625062).

Withdrawal modelling

A 2014 report examined the efficacy of the peptide anxiolytic Selank during modelling of withdrawal syndrome in rats with stable alcoholic motivation, meaning the animals had an established pattern of alcohol consumption before the withdrawal state was induced (PMID 24913576). Taken together, these three rodent papers describe Selank being administered in the context of ethanol exposure rather than describing what happens when a person drinks alcohol while a peptide is in circulation (PMID 27878720, PMID 24913576).

What these studies do not establish: none of them was designed as a human interaction study, none reported that combining the two is advisable or inadvisable, and none measured blood alcohol concentration handling, liver metabolism or additive sedation in humans (PMID 31625062).

Selank and benzodiazepines (diazepam)

The clearest drug-combination finding in this literature comes from a 2017 rat experiment reporting that Selank enhanced the effect of diazepam in reducing anxiety under unpredictable chronic mild stress conditions (PMID 28280289). The word the authors used was "enhances," which in that paper referred to an anxiety-related behavioural outcome in stressed rats rather than to a measured change in diazepam blood levels (PMID 28280289).

This is the type of result that pharmacologists describe as a pharmacodynamic interaction: two agents acting on a shared system produce a combined behavioural effect that differs from either alone. Because benzodiazepines act at the GABA-A receptor complex, an enhancement finding is mechanistically plausible alongside the GABAergic gene-expression work described below (PMID 28293190). The 2017 study did not report human data, and it did not evaluate sedation, respiratory outcomes or dependence-related endpoints (PMID 28280289).

Selank with GABA and olanzapine in cell culture

A 2017 in vitro study examined GABA, Selank and olanzapine and reported that each affected the expression of genes involved in GABAergic neurotransmission in IMR-32 cells, a human neuroblastoma line used as a neuronal model (PMID 28293190). Importantly, the researchers tested these agents in a cultured cell system, so the work speaks to overlapping molecular targets rather than to what happens when an antipsychotic and a peptide are used together in a living organism (PMID 28293190).

Readers sometimes see this paper cited as evidence that Selank "interacts with" olanzapine. The study design does not support that framing: the three compounds were characterised for their effects on a shared gene set, which is a comparison, not a co-administration interaction trial (PMID 28293190).

Caffeine: no published Selank interaction study

No study in the literature reviewed here examined Selank together with caffeine, coffee, energy drinks or other stimulants. There is no reported pharmacokinetic data, no behavioural co-administration model and no human observation for that pairing.

Mechanistic reasoning only — labelled as such, not a finding: researchers who discuss this pairing note that caffeine acts primarily as an adenosine receptor antagonist, while the Selank work described above concerns GABAergic and neurotrophin-related endpoints (PMID 28293190, PMID 31625062). Distinct primary targets do not rule out interaction at the level of arousal and anxiety-related behaviour, but no experiment in this set tested that possibility, so any statement about the combination is inference rather than evidence.

Food, fasting and route of administration

No identified study compared Selank administration in fed versus fasted states, examined the effect of a meal on absorption, or measured bioavailability differences related to food intake. The rodent studies discussed above administered the peptide under laboratory conditions and reported behavioural and biochemical outcomes rather than food-related pharmacokinetics (PMID 27878720, PMID 20919548).

Mechanistic reasoning only — labelled as such: peptides of this size are generally susceptible to proteolytic degradation in the gastrointestinal tract, which is why intranasal delivery has been the common experimental route in the Selank literature. That rationale explains why food-effect studies are largely absent from the record; it is not a measured result, and no verified paper in this set reported a food interaction of any kind.

Other commonly asked combinations

Several pairings appear frequently in discussion but have no matching published Selank study in the identified literature. Rather than infer, this page lists them as evidence gaps.

• SSRIs and other antidepressants: no co-administration study identified. The clinical literature includes a Russian report on the treatment of anxiety disorders with Selank, but that paper is a treatment study rather than a documented drug-drug interaction analysis (PMID 26356395).
• Semax and other nootropic peptides: no combination study identified. Separate Selank work examined learning and memory processes in experimental models without a second peptide (PMID 20919548).
• Nicotine, cannabinoids, opioids: no identified co-exposure studies in this set; the substance-related work located here concerns ethanol only (PMID 24913576).
• Vitamins, minerals and general supplements: no identified studies of any kind.

Summary table of examined combinations

Combination-related adverse events: What Studies Report

None of the identified papers was designed as a combination-safety or toxicology trial, and none of the reports summarised here presented an adverse-event table for Selank plus a second substance. The ethanol studies reported behavioural and biochemical outcomes in rodents rather than tolerability endpoints (PMID 27878720, PMID 31625062), and the diazepam study reported an anxiety-related behavioural outcome in stressed rats (PMID 28280289). Human tolerability information in this set is limited to a clinical report on the treatment of anxiety disorders with Selank, which was not structured as an interaction study (PMID 26356395). The accurate statement is therefore that combination adverse-event data are absent from this literature, not that combinations were found to be uneventful.

How to read this evidence base

1. Species matters. The alcohol and diazepam findings came from mice and rats, and rodent behavioural models do not translate directly to human experience (PMID 28280289).
2. Cell-culture work is molecular, not clinical. Gene-expression changes in a neuroblastoma line describe target overlap, not a clinical interaction (PMID 28293190).
3. Absence of a study is not absence of an effect. The lack of caffeine or food-effect research means the question has not been tested, which is different from a negative result.
4. Much of the record is regional. Several of the papers, including the learning and memory work and the anxiety-disorder treatment report, were published in Russian-language journals with limited independent replication (PMID 20919548, PMID 26356395).

Selank is not an approved drug in the United States and is handled as a research chemical in most jurisdictions outside Russia, which is one reason the interaction literature is thin compared with that of licensed anxiolytics.

References

• Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (Behavioural Neurology, 2017)
• GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells (Frontiers in Pharmacology, 2017)
• [Experimental optimization of learning and memory processes by selank] (Eksperimental'naia i Klinicheskaia Farmakologiia, 2010)
• [Optimization of the treatment of anxiety disorders with selank] (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2015)
• Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats (Bulletin of Experimental Biology and Medicine, 2019)
• Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice (Bulletin of Experimental Biology and Medicine, 2016)
• Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation (Bulletin of Experimental Biology and Medicine, 2014)